Bristol-Myers Squibb Co. (BMY)

Bristol-Myers Squibb Co. Aktie (BMY) Neueste Nachrichten

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

Zacks Investment Research

BMS reports four-year data from psoriasis treatment extension trial - Clinical Trials Arena

Clinical Trials Arena

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch

MarketWatch

Walmart Earnings & the State of the Consumer

Zacks Investment Research

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

Zacks Investment Research

FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated F - Benzinga

Benzinga

BMY: 3 Pharma Stocks Primed for May Investment Opportunities - StockNews.com

StockNews.com

FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma - Pharmaceutical Technology

Pharmaceutical Technology

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Zacks Investment Research

FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma - Pharmaceutical Technology

Pharmaceutical Technology

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

BioSpace

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

MarketWatch

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Pfizer: Best Trading Momentum Since 2021 And 6% Yield

Seeking Alpha

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

BioSpace

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch

MarketWatch

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda ... - Chronicle-Tribune

Chronicle-Tribune

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda ... - Business Wire

Business Wire

Drug Tech Co. Hires J&J Atty As Chief Strategy Officer - Law360

Law360

Why Bristol Myers Squibb turned to Ted Danson to promote a plaque psoriasis treatment - PR Week

PR Week

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch

MarketWatch

Why Bristol Myers Squibb turned to Ted Danson to promote a plaque psoriasis treatment - PR Week

PR Week

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC - Pharmaceutical Technology

Pharmaceutical Technology

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Zacks Investment Research

Bristol Myers fails to beat AstraZeneca in stage 3 lung cancer - FiercePharma

FiercePharma

Our company - Worldwide locations - Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0% - Defense World

Defense World

Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip

The Motley Fool

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know - Yahoo New Zealand News

Yahoo New Zealand News

Is Bristol Myers' Dividend in Danger?

The Motley Fool

Bristol Myers CEO Caforio to step down - Yahoo Movies Canada

Yahoo Movies Canada

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

MarketWatch

Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs - BenefitsPro

BenefitsPro

2 Beaten-Down Stocks to Buy and Hold for 10 Years

The Motley Fool

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields

Benzinga

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

MarketWatch

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

Zacks Investment Research

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

MarketWatch

A Look at Pharma ETFs Post Q1 Earnings

Zacks Investment Research

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

MarketWatch

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch

MarketWatch

Bristol Myers Squibb Co. stock rises Friday, still underperforms market - MarketWatch

MarketWatch

Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?

The Motley Fool

If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today

The Motley Fool

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

Zacks Investment Research

If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today - The Motley Fool

The Motley Fool

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Zacks Investment Research

3 Blue-Chip Bargains Trading At 52-Week Lows

Seeking Alpha

Bristol-Myers Squibb Stock: A Lost Decade? (NYSE:BMY) - Seeking Alpha

Seeking Alpha

3 Top ETFs to Buy for Passive Income in May

The Motley Fool